Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GILEAD SCIENCES, INC.GILD · Entity 405 | Chief Operating Officer | February 15, 2018 | February 23, 2018 |
| Quince Therapeutics, Inc.CRTX · Entity 7403 | Director | June 08, 2020 | June 09, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GILEAD SCIENCES, INC.
Report date February 15, 2018 · Filed February 23, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 25,612 |
Ending reported balance
After 2018-02-21 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-02-15 · Grant · Acquired 340 · Balance 16,152 F1: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan. Row 2 · 2018-02-21 · Grant · Acquired 9,460 · Balance 25,612 F2: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 2, 2017. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual satisfies the applicable service-vesting requirements by continuing in the Issuer's employ through December 31, 2018 and December 31, 2019, respectively. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan.
F2: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 2, 2017. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual satisfies the applicable service-vesting requirements by continuing in the Issuer's employ through December 31, 2018 and December 31, 2019, respectively.
Quince Therapeutics, Inc.
Report date June 08, 2020 · Filed June 09, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.73 · Expires 2030-06-07 | Direct | 11,029 |
Reported balance
After 2020-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-08 · Grant · Acquired 11,029 · Balance 11,029 F1: This option shall fully vest on the one-year anniversary of the grant date, subject to the reporting person's continued services as a member of the board of directors of Cortexyme, Inc. through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall fully vest on the one-year anniversary of the grant date, subject to the reporting person's continued services as a member of the board of directors of Cortexyme, Inc. through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 07, 2008 Filed Jan 9, 2008 23:35 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 10,000 | $46.80 | $468,000.00 |
DisclosureSEC source: 0001179110-08-000915 · edgar.xml · nonDerivative · entry 5 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,739 Read SEC document |
| January 07, 2008 Filed Jan 9, 2008 23:35 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,000 | $46.81 | $93,620.00 |
DisclosureSEC source: 0001179110-08-000915 · edgar.xml · nonDerivative · entry 4 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,739 Read SEC document |
| January 07, 2008 Filed Jan 9, 2008 23:35 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,000 | $46.85 | $234,250.00 |
DisclosureSEC source: 0001179110-08-000915 · edgar.xml · nonDerivative · entry 3 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,739 Read SEC document |
| January 07, 2008 Filed Jan 9, 2008 23:35 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 20,000 | $17.68 | $353,500.00 |
DisclosureSEC source: 0001179110-08-000915 · edgar.xml · nonDerivative · entry 2 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,739 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2008 Filed Jan 9, 2008 23:35 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 10,000 | $16.01 | $160,100.00 |
DisclosureSEC source: 0001179110-08-000915 · edgar.xml · nonDerivative · entry 1 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,739 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amount of securities beneficially owned following the reported transactions includes 58 shares acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan on December 31, 2007 Read SEC document |
| October 09, 2007 Filed Oct 11, 2007 00:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $17.68 | $0.00 |
DisclosureSEC source: 0001179110-07-019664 · edgar.xml · derivative · entry 21 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 273,790 Underlying: Common Stock · 20,000 shares Expires 2014-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Options vest over a five year period with 20% vesting November 2, 2005, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, and will be fully vested on November 2, 2009. Read SEC document |
| October 09, 2007 Filed Oct 11, 2007 00:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $16.01 | $0.00 |
DisclosureSEC source: 0001179110-07-019664 · edgar.xml · derivative · entry 20 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,340 Underlying: Common Stock · 10,000 shares Expires 2015-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Options vest over a five year period with 20% vesting January 26, 2006, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, and will be fully vested on January 26, 2010. Read SEC document |
| October 09, 2007 Filed Oct 11, 2007 00:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,000 | $41.65 | $41,650.00 |
DisclosureSEC source: 0001179110-07-019664 · edgar.xml · nonDerivative · entry 19 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,681 F1 · shares: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan established by Mr. Young on May 29, 2007. Read SEC document |
| October 09, 2007 Filed Oct 11, 2007 00:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,000 | $41.61 | $41,610.00 |
DisclosureSEC source: 0001179110-07-019664 · edgar.xml · nonDerivative · entry 18 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,681 F1 · shares: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan established by Mr. Young on May 29, 2007. Read SEC document |
| October 09, 2007 Filed Oct 11, 2007 00:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,000 | $41.56 | $83,120.00 |
DisclosureSEC source: 0001179110-07-019664 · edgar.xml · nonDerivative · entry 17 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,681 F1 · shares: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan established by Mr. Young on May 29, 2007. Read SEC document |
| October 09, 2007 Filed Oct 11, 2007 00:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,000 | $41.64 | $41,640.00 |
DisclosureSEC source: 0001179110-07-019664 · edgar.xml · nonDerivative · entry 16 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,681 F1 · shares: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan established by Mr. Young on May 29, 2007. Read SEC document |
| October 09, 2007 Filed Oct 11, 2007 00:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,000 | $41.62 | $83,240.00 |
DisclosureSEC source: 0001179110-07-019664 · edgar.xml · nonDerivative · entry 15 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,681 F1 · shares: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan established by Mr. Young on May 29, 2007. Read SEC document |
| October 09, 2007 Filed Oct 11, 2007 00:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 500 | $41.51 | $20,755.00 |
DisclosureSEC source: 0001179110-07-019664 · edgar.xml · nonDerivative · entry 14 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,681 F1 · shares: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan established by Mr. Young on May 29, 2007. Read SEC document |
| October 09, 2007 Filed Oct 11, 2007 00:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,000 | $41.59 | $124,770.00 |
DisclosureSEC source: 0001179110-07-019664 · edgar.xml · nonDerivative · entry 13 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,181 F1 · shares: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan established by Mr. Young on May 29, 2007. Read SEC document |
| October 09, 2007 Filed Oct 11, 2007 00:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,500 | $41.65 | $104,125.00 |
DisclosureSEC source: 0001179110-07-019664 · edgar.xml · nonDerivative · entry 12 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,181 F1 · shares: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan established by Mr. Young on May 29, 2007. Read SEC document |
| October 09, 2007 Filed Oct 11, 2007 00:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 500 | $41.66 | $20,830.00 |
DisclosureSEC source: 0001179110-07-019664 · edgar.xml · nonDerivative · entry 11 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,681 F1 · shares: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan established by Mr. Young on May 29, 2007. Read SEC document |
| October 09, 2007 Filed Oct 11, 2007 00:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,000 | $41.55 | $41,550.00 |
DisclosureSEC source: 0001179110-07-019664 · edgar.xml · nonDerivative · entry 10 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,181 F1 · shares: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan established by Mr. Young on May 29, 2007. Read SEC document |
| October 09, 2007 Filed Oct 11, 2007 00:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,500 | $41.60 | $228,800.00 |
DisclosureSEC source: 0001179110-07-019664 · edgar.xml · nonDerivative · entry 9 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,181 F1 · shares: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan established by Mr. Young on May 29, 2007. Read SEC document |
| October 09, 2007 Filed Oct 11, 2007 00:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,500 | $41.58 | $145,530.00 |
DisclosureSEC source: 0001179110-07-019664 · edgar.xml · nonDerivative · entry 8 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,681 F1 · shares: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan established by Mr. Young on May 29, 2007. Read SEC document |
| October 09, 2007 Filed Oct 11, 2007 00:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,000 | $41.46 | $41,460.00 |
DisclosureSEC source: 0001179110-07-019664 · edgar.xml · nonDerivative · entry 7 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,181 F1 · shares: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan established by Mr. Young on May 29, 2007. Read SEC document |
| October 09, 2007 Filed Oct 11, 2007 00:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,000 | $41.53 | $41,530.00 |
DisclosureSEC source: 0001179110-07-019664 · edgar.xml · nonDerivative · entry 6 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,181 F1 · shares: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan established by Mr. Young on May 29, 2007. Read SEC document |
| October 09, 2007 Filed Oct 11, 2007 00:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,000 | $41.50 | $83,000.00 |
DisclosureSEC source: 0001179110-07-019664 · edgar.xml · nonDerivative · entry 5 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,181 F1 · shares: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan established by Mr. Young on May 29, 2007. Read SEC document |
| October 09, 2007 Filed Oct 11, 2007 00:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 500 | $41.49 | $20,745.00 |
DisclosureSEC source: 0001179110-07-019664 · edgar.xml · nonDerivative · entry 4 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,181 F1 · shares: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan established by Mr. Young on May 29, 2007. Read SEC document |
| October 09, 2007 Filed Oct 11, 2007 00:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,000 | $41.43 | $82,860.00 |
DisclosureSEC source: 0001179110-07-019664 · edgar.xml · nonDerivative · entry 3 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,681 F1 · shares: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan established by Mr. Young on May 29, 2007. Read SEC document |
| October 09, 2007 Filed Oct 11, 2007 00:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 20,000 | $17.68 | $353,500.00 |
DisclosureSEC source: 0001179110-07-019664 · edgar.xml · nonDerivative · entry 2 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,681 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan established by Mr. Young on May 29, 2007. Read SEC document |
| October 09, 2007 Filed Oct 11, 2007 00:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 10,000 | $16.01 | $160,100.00 |
DisclosureSEC source: 0001179110-07-019664 · edgar.xml · nonDerivative · entry 1 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,681 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan established by Mr. Young on May 29, 2007. Read SEC document |
| July 03, 2007 Filed Jul 6, 2007 22:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $17.68 | $0.00 |
DisclosureSEC source: 0001179110-07-014591 · edgar.xml · derivative · entry 5 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,790 Underlying: Common Stock · 20,000 shares Expires 2014-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Options vest over a five year period with 20% vesting November 2, 2005, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, and will be fully vested on November 2, 2009. Read SEC document |
| July 03, 2007 Filed Jul 6, 2007 22:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $16.01 | $0.00 |
DisclosureSEC source: 0001179110-07-014591 · edgar.xml · derivative · entry 4 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,340 Underlying: Common Stock · 10,000 shares Expires 2015-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Options vest over a five year period with 20% vesting January 26, 2006, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, and will be fully vested on January 26, 2010. Read SEC document |
| July 03, 2007 Filed Jul 6, 2007 22:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 30,000 | $39.36 | $1,180,854.00 |
DisclosureSEC source: 0001179110-07-014591 · edgar.xml · nonDerivative · entry 3 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,681 F1 · shares: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan established by Mr. Young on May 29, 2007. F2 · balance_after: All shares and dollar amounts reflect a two-for-one split that was effected on June 22, 2007 benefiting all shareholders of record as of May 24, 2007. F3 · balance_after: Amount of securities beneficially owned following the reported transactions includes 733 shares acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan on June 29, 2007. Read SEC document |
| July 03, 2007 Filed Jul 6, 2007 22:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 20,000 | $17.68 | $353,500.00 |
DisclosureSEC source: 0001179110-07-014591 · edgar.xml · nonDerivative · entry 2 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,681 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan established by Mr. Young on May 29, 2007. F2 · balance_after: All shares and dollar amounts reflect a two-for-one split that was effected on June 22, 2007 benefiting all shareholders of record as of May 24, 2007. Read SEC document |
| July 03, 2007 Filed Jul 6, 2007 22:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 10,000 | $16.01 | $160,100.00 |
DisclosureSEC source: 0001179110-07-014591 · edgar.xml · nonDerivative · entry 1 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,681 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan established by Mr. Young on May 29, 2007. F2 · balance_after: All shares and dollar amounts reflect a two-for-one split that was effected on June 22, 2007 benefiting all shareholders of record as of May 24, 2007. Read SEC document |
| May 08, 2007 Filed May 10, 2007 20:24 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $82.96 | $0.00 |
DisclosureSEC source: 0001179110-07-009678 · edgar.xml · derivative · entry 1 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2017-05-08 F1 · derivative.exercise_date: Options vest over a five year period beginning 5/08/2008, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, ending on 5/08/2012. Read SEC document |
| February 20, 2007 Filed Feb 23, 2007 00:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $35.35 | $0.00 |
DisclosureSEC source: 0001179110-07-004570 · edgar.xml · derivative · entry 18 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,895 Underlying: Common Stock · 20,000 shares Expires 2014-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Options vested 20% on November 2, 2005, the first anniversary of the grant. The balance will vest 5% every three months thereafter until fully vested on November 2, 2009. Read SEC document |
| February 20, 2007 Filed Feb 23, 2007 00:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $32.02 | $0.00 |
DisclosureSEC source: 0001179110-07-004570 · edgar.xml · derivative · entry 17 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,670 Underlying: Common Stock · 10,000 shares Expires 2015-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Options vested 20% on January 26, 2006, the first anniversary of the grant. The balance will vest 5% every three months thereafter until fully vested on January 26, 2010. Read SEC document |
| February 20, 2007 Filed Feb 23, 2007 00:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,800 | $72.33 | $202,524.00 |
DisclosureSEC source: 0001179110-07-004570 · edgar.xml · nonDerivative · entry 16 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,974 F1 · balance_after: Amount of securities beneficially owned following the reported transactions includes 720 shares acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan on June 30, 2006 Read SEC document |
| February 20, 2007 Filed Feb 23, 2007 00:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 100 | $72.36 | $7,236.00 |
DisclosureSEC source: 0001179110-07-004570 · edgar.xml · nonDerivative · entry 15 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,774 Read SEC document |
| February 20, 2007 Filed Feb 23, 2007 00:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,400 | $72.28 | $173,472.00 |
DisclosureSEC source: 0001179110-07-004570 · edgar.xml · nonDerivative · entry 14 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,874 Read SEC document |
| February 20, 2007 Filed Feb 23, 2007 00:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,591 | $72.34 | $404,452.94 |
DisclosureSEC source: 0001179110-07-004570 · edgar.xml · nonDerivative · entry 13 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,274 Read SEC document |
| February 20, 2007 Filed Feb 23, 2007 00:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,668 | $72.32 | $120,629.76 |
DisclosureSEC source: 0001179110-07-004570 · edgar.xml · nonDerivative · entry 12 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,865 Read SEC document |
| February 20, 2007 Filed Feb 23, 2007 00:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,580 | $72.37 | $114,344.60 |
DisclosureSEC source: 0001179110-07-004570 · edgar.xml · nonDerivative · entry 11 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,533 Read SEC document |
| February 20, 2007 Filed Feb 23, 2007 00:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,000 | $72.26 | $72,260.00 |
DisclosureSEC source: 0001179110-07-004570 · edgar.xml · nonDerivative · entry 10 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,113 Read SEC document |
| February 20, 2007 Filed Feb 23, 2007 00:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 234 | $72.27 | $16,911.18 |
DisclosureSEC source: 0001179110-07-004570 · edgar.xml · nonDerivative · entry 9 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,113 Read SEC document |
| February 20, 2007 Filed Feb 23, 2007 00:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 500 | $72.31 | $36,155.00 |
DisclosureSEC source: 0001179110-07-004570 · edgar.xml · nonDerivative · entry 8 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,347 Read SEC document |
| February 20, 2007 Filed Feb 23, 2007 00:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,100 | $72.29 | $79,519.00 |
DisclosureSEC source: 0001179110-07-004570 · edgar.xml · nonDerivative · entry 7 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,847 Read SEC document |
| February 20, 2007 Filed Feb 23, 2007 00:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 400 | $72.30 | $28,920.00 |
DisclosureSEC source: 0001179110-07-004570 · edgar.xml · nonDerivative · entry 6 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,947 Read SEC document |
| February 20, 2007 Filed Feb 23, 2007 00:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 731 | $72.23 | $52,800.13 |
DisclosureSEC source: 0001179110-07-004570 · edgar.xml · nonDerivative · entry 5 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,347 Read SEC document |
| February 20, 2007 Filed Feb 23, 2007 00:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,728 | $72.25 | $124,848.00 |
DisclosureSEC source: 0001179110-07-004570 · edgar.xml · nonDerivative · entry 4 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,078 Read SEC document |
| February 20, 2007 Filed Feb 23, 2007 00:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 10,168 | $72.24 | $734,536.32 |
DisclosureSEC source: 0001179110-07-004570 · edgar.xml · nonDerivative · entry 3 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,806 Read SEC document |
| February 20, 2007 Filed Feb 23, 2007 00:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 20,000 | $35.35 | $707,000.00 |
DisclosureSEC source: 0001179110-07-004570 · edgar.xml · nonDerivative · entry 2 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,974 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 20, 2007 Filed Feb 23, 2007 00:25 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 10,000 | $32.02 | $320,200.00 |
DisclosureSEC source: 0001179110-07-004570 · edgar.xml · nonDerivative · entry 1 YOUNG KEVIN · CIK 0001303643 · EVP, Commercial Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,974 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.